Indivior Plc (NASDAQ:INDV) stock plunged following the company’s fiscal year 2025 guidance that fell short of Street expectations. Addiction and mental illnesses-focused Indivior reported ...

(Reuters) - Shares of drugmaker Indivior Plc (INDV.L) fell as much as 10 percent on Wednesday, a day after the company lost a legal battle that will allow an Indian generic rival to sell a copycat ...

(Reuters) - Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug. The British ...

Guidance for 2025 projects total net revenue between $955M and $1.25B, reflecting a decline from 2024 due to erosion in SUBOXONE Film net revenue and the discontinuation of PERSERIS. SUBLOCADE’s 2025 ...

* Co claims own generic gets 50 pct of market share * Co makes "encouraging progress" in delivering Sublocade * Stock closes up 5.2 percent (Adds graphics, CFO comment, details on DoJ investigation) ...

Embattled drugmaker Indivior said on Thursday the hit to revenue this year from a cheap copy of its top-selling opium addiction drug would be less than feared, as cost cutting helped it to deliver a ...

Sept 12 (Reuters) - Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another ...